Signaturefd LLC reduced its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 32.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,623 shares of the biopharmaceutical company's stock after selling 37,464 shares during the period. Signaturefd LLC's holdings in Pfizer were worth $2,112,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer in the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter worth about $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the fourth quarter worth about $31,000. Finally, Sierra Ocean LLC acquired a new stake in Pfizer during the fourth quarter worth about $34,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research firms recently issued reports on PFE. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday. Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Citigroup cut their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, StockNews.com cut shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.
Get Our Latest Stock Report on PFE
Pfizer Stock Up 1.0 %
Shares of PFE stock traded up $0.26 during trading on Tuesday, reaching $26.31. The company's stock had a trading volume of 32,949,032 shares, compared to its average volume of 35,799,303. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $149.09 billion, a price-to-earnings ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.61. The stock's 50-day moving average price is $26.22 and its 200 day moving average price is $27.10. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the business posted $0.10 earnings per share. The business's quarterly revenue was up 24.7% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.
Insider Buying and Selling
In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by insiders.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
